中国医学创新Issue(12)：31-33,34,4.DOI:10.3969/j.issn.1674-4985.2014.12.011
贝伐珠单抗联合化疗治疗难治性实体瘤的疗效和安全性
The Clinical Observation of Bevacizumab Combined with Chemotherapy for Refractory Advanced Solid Tumors
摘要
Abstract
Objective:To determine the safety and efficacy of bevacizumab in combination with different chemotherapy regimens for second-line and second-line above treatment of refractory advanced solid tumors. Method:From October 2011 to september 2012, fifty three patients were enrolled. The dose of bevacizumab was 7.5 mg/kg ,iv drip,d1. The chemotherapy regimens were chosen depending on the type of tumor and the past medical history. All the plans with 3 weeks for a cycle. Result:53 patients with advanced solid tumors were followed up for 1-12 months, 50 cases could be evaluated:PR were 23 cases, SD were 18 cases, PD were 9 cases, the effective rate was 46.0%, the disease control rates was 82.0%;PFS was 5.4 months(95%CI:3.704-6.913 months), OS was 10.9 months(95%CI:9.255-14.830 months).The common adverse reaction were:the bone marrow suppression, fatigue, diarrhea and abdominal pain, hypertension, etc.;3-4 adverse reaction were:neutropenia 16.0%(8/50), diarrhea 12.0%(6/50), fatigue 10.0%(5/50), hypertension, 8.0%(4/50). The cumulative incidence of serious adverse events was 20.0%(10/50), the most common for pneumonia and abdominal pain, SVT were 4.0%(2/50)respectively;dehydration, diarrhea, lack of sexual fever, sepsis were 2.0%(1/50)respectively. Conclusion:Bevacizumab in combination with different chemotherapy regimen in treatment for late refractory solid tumors is safe and effective.关键词
贝伐珠单抗/难治性实体肿瘤/化疗/抗血管生成Key words
Bevacizumab/Refractory advanced solid tumors/Chemotherapy/Anti-angiogenesis引用本文复制引用
李宝秀,曹小飞,翁成荫,方喜生,毛海波,关明媚,刘国龙..贝伐珠单抗联合化疗治疗难治性实体瘤的疗效和安全性[J].中国医学创新,2014,(12):31-33,34,4.基金项目
2012年度广东省科技计划（01078650166731031）；2011年度广东省医学科研基金（A2011689）；广州市医药卫生科技基金 （）
